sort by
approximate search
1shortlisttitle datasearch history  
results search [or] ISN:0000000115704164 | 1 hits
Person
ISNI: 
0000 0001 1570 4164
Name: 
Bukowski, R. M.
Bukowski, Ronald
Bukowski, Ronald M.
Dates: 
1942-
Creation class: 
article
Computer file
cre
Language material
txt
Creation role: 
author
contributor
editor
redactor
Related names: 
Figlin, Robert A.
Finke, James H. (1944-)
Finke, James H. (1944-))
Klein, Eric A. (1955-)
Macklis, Roger
Markman, Maurie
McLain, Robert F.
Montie, James E.
Motzer, Robert J.
Novick, Andrew C.
Ozols, Robert F.
Pontes, J. Edson
Titles: 
2ND SYMPOSIUM ON IMMUNOBIOLOGY OF RENAL CELL CARCINOMA
3RD SYMPOSIUM ON THE BIOLOGY OF RENAL CELL CARCINOMA
Additional Tyrosine Kinase Inhibitors in Renal Cell Carcinoma
adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial, An
Adjuvant subcutaneous interleukin-2 in patients with resected renal cell carcinoma: a pilot study.
Adjuvant Therapy for Renal Cell Carcinoma: Targeted Approaches
Adult cystic nephroma and mixed epithelial and stromal tumor of the kidney are the same disease entity: molecular and histologic evidence.
Alternating combination chemotherapy in patients with extragonadal germ cell tumors. A Southwest Oncology Group study.
Amifostine (Ethyol): dosing, administration and patient management guidelines.
Anti-angiogenic targets in the treatment of advanced renal cell carcinoma.
Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.
Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy.
Attenuation of drug-stimulated topoisomerase II-DNA cleavable complex formation in wild-type HL-60 cells treated with an intracellular calcium buffer is correlated with decreased cytotoxicity and site-specific hypophosphorylation of topoisomerase IIalpha.
Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study.
Biologic therapy in patients receiving salvage treatment.
BIOLOGY OF RENAL CELL CARCINOMA
Biomarkers predicting outcome in patients with advanced renal cell carcinoma: Results from sorafenib phase III Treatment Approaches in Renal Cancer Global Evaluation Trial.
c-IAP1 is overexpressed in HL-60 cells selected for doxorubicin resistance: effects on etoposide-induced apoptosis.
Cancer immunotherapy at the crossroads : how tumors evade immunity and what can be done
Cancer in the Spine Comprehensive Care
Carbonic Anhydrase IX: Biology and Clinical Approaches
Casein kinase I delta/epsilon phosphorylates topoisomerase IIalpha at serine-1106 and modulates DNA cleavage activity.
Casein kinase I δ/ε phosphorylates topoisomerase IIα at serine-1106 and modulates DNA cleavage activity.
Characterization of tumor-infiltrating lymphocyte subsets from human renal cell carcinoma: Specific reactivity defined by cytotoxicity, interferon- gamma secretion, and proliferation
Chemokines in Renal Cell Carcinoma: Implications for Tumor Angiogenesis and Metastasis
Clinical activity of sorafenib and sunitinib in renal cell carcinoma refractory to previous vascular endothelial growth factor-targeted therapy: two case reports.
Clinical and immunologic effects of subcutaneously administered interleukin-12 and interferon alfa-2b: phase I trial of patients with metastatic renal cell carcinoma or malignant melanoma.
Clinical and immunomodulatory effects of bevacizumab and low-dose interleukin-2 in patients with metastatic renal cell carcinoma: results from a phase II trial.
Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.
Clinical management of renal tumors
Clinical results and characterization of tumor-infiltrating lymphocytes with or without recombinant interleukin 2 in human metastatic renal cell carcinoma.
Combination chemotherapy including VP-16 for poor prognosis germ cell neoplasms.
Combination radiation and chemotherapy for the treatment of squamous cell carcinoma of the male and female urethra.
critical review of immunotherapy of disseminated renal adenocarcinoma, A
Current approaches in cytoprotection : the role of amifostine (Ethyol[R]) in altering and ameliorating toxicities in Cancer therapy
current role of angiogenesis inhibitors in the treatment of renal cell carcinoma., The
CXC Chemokines IP-10 and Mig Are Necessary for IL-12-Mediated Regression of the Mouse RENCA Tumor, The
Cytokine and chemokine expression in tumors of mice receiving systemic therapy with IL-12
Cytokine combinations: therapeutic use in patients with advanced renal cell carcinoma.
Cytokine therapy for metastatic renal cell carcinoma.
Cytoprotection in the treatment of pediatric cancer: review of current strategies in adults and their application to children.
Dead or dying: necrosis versus apoptosis in caspase-deficient human renal cell carcinoma.
Defective granzyme B gene expression and lytic response in T lymphocytes infiltrating human renal cell carcinoma
Degradation of NF- Kappa B in T Cells by Gangliosides Expressed on Renal Cell Carcinomas
Development of novel signal transduction inhibitors; recent phase I trials.
Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma.
Disease-associated Bias in T Helper Type 1 (Th1)/Th2 CD4 super(+) T Cell Responses Against MAGE-6 in HLA-DRB1*0401 super(+) Patients With Renal Cell Carcinoma or Melanoma
Disease stage variation in CD4+ and CD8+ T-cell reactivity to the receptor tyrosine kinase EphA2 in patients with renal cell carcinoma.
Downregulation of topoisomerase II beta in myeloid leukemia cell lines leads to activation of apoptosis following all-trans retinoic acid-induced differentiation/growth arrest
Effect of Renal Cell Carcinomas on the Development of Type 1 T-Cell Responses
Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma.
EGFR and HER2: Relevance in Renal Cell Carcinoma
Enhancement in specific CD8+ T cell recognition of EphA2+ tumors in vitro and in vivo after treatment with ligand agonists.
EphA2: A Novel Target in Renal Cell Carcinoma
Evaluation of combination chemotherapy and phase II agents in pancreatic adenocarcinoma. A Southwest Oncology Group study.
Evaluation of fludarabine phosphate in renal cell carcinoma: a Southwest Oncology Group Study.
Evolving role of pegylated interferons in metastatic renal cell carcinoma.
Expression of EphA2 is prognostic of disease-free interval and overall survival in surgically treated patients with renal cell carcinoma.
F-18 fluorodeoxyglucose positron emission tomography in the evaluation of distant metastases from renal cell carcinoma.
FIRST INTERNATIONAL KIDNEY CANCER SYMPOSIUM
Gangliosides expressed by the renal cell carcinoma cell line SK-RC-45 are involved in tumor-induced apoptosis of T cells.
GM1 and Tumor Necrosis Factor- alpha , Overexpressed in Renal Cell Carcinoma, Synergize to Induce T-Cell Apoptosis
GM2 Expression in Renal Cell Carcinoma: Potential Role in Tumor-Induced T-Cell Dysfunction
Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib.
Immunomodulatory effects of interleukin-2 and interleukin-4 in patients with malignancy
Immunomodulatory effects of recombinant interleukin-3 treatment on human alveolar macrophages and monocytes.
Immunotherapy in renal cell carcinoma.
Impaired activation of NFkappaB in T cells from a subset of renal cell carcinoma patients is mediated by inhibition of phosphorylation and degradation of the inhibitor, IkappaBalpha.
Improving Immunotherapy by Conditionally Enhancing MHC Class I Presentation of Tumor Antigen-Derived Peptide Epitopes
Induction by interleukin-2 of oligoclonal expansion of cultured tumor-infiltrating lymphocytes.
Inhibition of NF- Kappa B Activity in Human T Lymphocytes Induces Caspase-Dependent Apoptosis Without Detectable Activation of Caspase-1 and -3
Inhibition of NF- Kappa B and Proteasome Activity in Tumors: Can We Improve the Therapeutic Potential of Topoisomerase I and Topoisomerase II Poisons
Inhibition of NF-kappaB and proteasome activity in tumors: can we improve the therapeutic potential of topoisomerase I and topoisomerase II poisons.
Inhibition of Proteasome Activity by Bortezomib in Renal Cancer Cells Is p53 Dependent and VHL Independent
Innovations and challenges in renal cancer: consensus statement from the first international conference.
Innovations and challenges in renal cancer: summary statement from the Third Cambridge Conference.
Integrin alpha 5 beta 1 as a Novel Therapeutic Target in Renal Cancer
Interferon-gamma and CXC chemokine induction by interleukin 12 in renal cell carcinoma.
Interferons and Interleukin-2: Molecular Basis of Activity and Therapeutic Results
Interleukin-2: use in solid tumors.
Interleukin 7 enhances the proliferation and effector function of tumor-infiltrating lymphocytes from renal-cell carcinoma.
Is Pazopanib Safe and Efficacious in Patients with Metastatic Renal Cell Carcinoma?
MAGE-6 encodes HLA-DRbeta1*0401-presented epitopes recognized by CD4+ T cells from patients with melanoma or renal cell carcinoma.
management of recurrent ovarian cancer., The
Mechanisms of immune evasion by renal cell carcinoma: tumor-induced T-lymphocyte apoptosis and NFkappaB suppression.
Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.
Modulation of vinblastine cytotoxicity by dilantin (phenytoin) or the protein phosphatase inhibitor okadaic acid involves the potentiation of anti-mitotic effects and induction of apoptosis in human tumour cells
Molecular Biology of Kidney Cancer and Its Clinical Translation into Treatment Strategies, The
Molecular Genetics in Inherited Renal Cell Carcinoma: Identification of Targets in the Hereditary Syndromes
Molecular Markers for Predicting Prognosis of Renal Cell Carcinoma
Molecular Targets in Renal Tumors: Pathologic Assessment
Monoclonal Antibody G250 Recognizing Carbonic Anhydrase IX in Renal Cell Carcinoma: Biological and Clinical Studies
Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2.
need for cytoprotection., The
Novel antineoplastic agents.
Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma.
Pegylated interferon alfa-2b as treatment of patients with solid tumors.
Pegylated interferon alfa-2b treatment for patients with solid tumors: a phase I/II study.
PHASE 1 CLINICAL TRIAL OF A COMBINATION OF ANTI-GD3 MONO
Phase 1 trial of Anvirzel registered in patients with refractory solid tumors
Phase 1 trial of Anvirzel(TM) in patients with refractory solid tumors
Phase 1 Trial of Subcutaneous IL-6 in Patients With Refractory Cancer: Clinical and Biologic Effects
PHASE 1B CLINICAL TRIAL OF TIL/R1L2/RENAL CARCINOMA
Phase 2 trial of talactoferrin in previously treated patients with metastatic renal cell carcinoma.
PHASE I CLINICAL TRIAL OF A COMBINATION OF ANTI-GD OF
PHASE I CLINICAL TRIAL OF GM-CSF IN LUNG CANCER
PHASE I/II--CLINICAL BIOLOGICAL RESPONSE MODIFICATION
Phase I/II study of GTI-2040 and capecitabine in patients with renal cell carcinoma, A
Phase I/II Study of Vaccination With Electrofused Allogeneic Dendritic Cells/Autologous Tumor-derived Cells in Patients With Stage IV Renal Cell Carcinoma
Phase I/II trial of 5-fluorouracil and a noncytotoxic dose level of suramin in patients with metastatic renal cell carcinoma.
phase I trial of 5-fluorouracil, folinic acid, and alpha-2a-interferon in patients with metastatic colorectal carcinoma., A
Phase I trial of cisplatin, WR-2721, and the murine monoclonal antibody R24 in patients with metastatic melanoma: clinical and biologic effects.
Phase I trial of consensus interferon in patients with metastatic renal cell carcinoma: toxicity and immunological effects.
Phase I trial of continuous infusion interleukin-2 and doxorubicin in patients with refractory malignancies.
Phase I trial of continuous infusion recombinant human interleukin-4 in patients with cancer.
Phase I trial of continuous infusion recombinant interleukin-2 and intermittent recombinant interferon-alpha 2a: clinical effects.
Phase I trial of natural human interferon beta in metastatic malignancy.
Phase I trial of PEG-interferon and recombinant IL-2 in patients with metastatic renal cell carcinoma
Phase I trial of phenoxodiol delivered by continuous intravenous infusion in patients with solid cancer
Phase I trial of recombinant granulocyte-macrophage colony-stimulating factor in patients with lung cancer: clinical and immunologic effects.
Phase I trial of subcutaneous interleukin 3 in patients with refractory malignancy: hematological, immunological, and pharmacodynamic findings.
Phase I trial of subcutaneous recombinant macrophage colony-stimulating factor: clinical and immunomodulatory effects.
Phase I trial of thalidomide and Interleukin-2 in patients with metastatic renal cell carcinoma
Phase I trial of vinorelbine and diphenylhydantoin in patients with refractory carcinoma.
Phase I trial of weekly docetaxel and gemcitabine in patients with refractory malignancies.
Phase II study of lenalidomide in patients with metastatic renal cell carcinoma.
Phase II study of the efficacy and safety of oral GD0039 in patients with locally advanced or metastatic renal cell carcinoma
Phase II trial of capecitabine and rHu-interferon-alpha-2a in patients with metastatic renal cell carcinoma, limited efficacy, and moderate toxicity.
Phase II trial of chlorozotocin and fluorouracil in islet cell carcinoma: a Southwest Oncology Group study.
phase II trial of combination chemotherapy in patients with metastatic carcinoid tumors. A Southwest Oncology Group Study., A
Phase II trial of dimethyltriazenoimidazole carboxamide in patients with metastatic carcinoid. A Southwest Oncology Group study.
Phase II trial of high-dose intermittent interleukin-2 in metastatic renal cell carcinoma: a Southwest Oncology Group study.
Phase II trial of interleukin-2 and interferon- alpha in patients with renal cell carcinoma: Clinical results and immunologic correlates of response
Phase II trial of mitotane and cisplatin in patients with adrenal carcinoma: a Southwest Oncology Group study.
Phase II trial of pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients., A
Phase II trial of sequential chemotherapy and low-dose radiotherapy in advanced gastric adenocarcinoma. A Southwest Oncology Group Pilot Study.
Phosphorylation of Serine 1106 in the Catalytic Domain of Topoisomerase II alpha Regulates Enzymatic Activity and Drug Sensitivity
PI3K/Akt/mTOR Pathway: A Growth and Proliferation Pathway
Pleiotropic effects of cytokines: clinical and preclinical studies.
Polyethylene glycol conjugated interleukin-2: clinical and immunologic effects in patients with advanced renal cell carcinoma.
population-based study evaluating the impact of sunitinib on overall survival in the treatment of patients with metastatic renal cell cancer., A
Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody.
Prognostic factors associated with long-term survival in previously untreated metastatic renal cell carcinoma
Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study.
Prognostic factors in patients with advanced renal cell carcinoma: development of an international kidney cancer working group.
Prognostic factors of metastatic renal cell carcinoma after failure of immunotherapy: new paradigm from a large phase III trial with shark cartilage extract AE 941.
Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma.
prognostic significance of epidermal growth factor receptor expression in clear-cell renal cell carcinoma: a call for standardized methods for immunohistochemical evaluation., The
Prolonged complete responses and near-complete responses to sunitinib in metastatic renal cell carcinoma.
Proteasome inhibition with bortezomib enhances activity of topoisomerase I-targeting drugs by NF-kappaB-independent mechanisms.
Proteasome-NF Kappa B Signaling Pathway: Relevance in RCC
Randomized Multicenter Phase II Trial of Subcutaneous Recombinant Human Interleukin-12 Versus Interferon-α2a for Patients with Advanced Renal Cell Carcinoma
Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer.
Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma.
Rapid analysis of docetaxel in human plasma by tandem mass spectrometry with on-line sample extraction.
Renal cell cancer
Renal cell carcinoma : immunotherapy and cellular biology
Renal cell carcinoma : molecular targets and clinical applications
Renal Cell Carcinoma Tumors Induce T Cell Apoptosis through Receptor-Dependent and Receptor-Independent Pathways
Resistance to interleukin 6 in human non-small cell lung carcinoma cell lines: role of receptor components.
Restoring Host Antitumoral Immunity: How Coregulatory Molecules Are Changing the Approach to the Management of Renal Cell Carcinoma
Retroperitoneal malignancies several years after initial treatment of germ cell cancer of the testis.
Role of Gangliosides in Renal Cell Carcinoma, The
Role of Hepatocyte Growth Factor Pathway Signaling in Renal Cell Carcinoma, The
Safety and Efficacy of Sorafenib in Elderly Patients Treated in the North American Advanced Renal Cell Carcinoma Sorafenib Expanded Access Program
Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America.
Selective cytokine gene expression in renal cell carcinoma tumor cells and tumor-infiltrating lymphocytes
Sensitization of DNA damage-induced apoptosis by the proteasome inhibitor PS-341 is p53 dependent and involves target proteins 14-3-3 sigma and survivin
Sensitization of DNA damage-induced apoptosis by the proteasome inhibitor PS-341 is p53 dependent and involves target proteins 14-3-3sigma and survivin.
Sequential use of targeted agents in the treatment of renal cell carcinoma.
Signal transduction abnormalities in T lymphocytes from patients with advanced renal carcinoma: clinical relevance and effects of cytokine therapy.
Smac/DIABLO: A Proapoptotic Molecular Target in Renal Cell Cancer
Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.
Sorafenib in advanced clear-cell renal-cell carcinoma.
Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab.
SOUTHWEST ONCOLOGY GROUP
Sunitinib and Axitinib in Renal Cell Carcinoma
Sunitinib efficacy against advanced renal cell carcinoma.
Sunitinib-induced macrocytosis in patients with metastatic renal cell carcinoma.
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.
SYMPOSIUM ON IMMUNOBIOLOGY OF RENAL CELL CARCINOMA
T cells infiltrating non-Hodgkin's B cell lymphomas show altered tyrosine phosphorylation pattern even though T cell receptor/CD3-associated kinases are present
T lymphocytes infiltrating renal cell carcinoma have a reduced expression of transferrin receptor.
Targeted therapy for cytokine-refractory metastatic renal cell carcinoma, and treatment in the community.
Targeted Therapy for Metastatic Renal Cell Carcinoma: Overview
Telomerase activity in stage II colorectal carcinoma.
Therapy and outcome of small cell carcinoma of the kidney: report of two cases and a systematic review of the literature.
Thrombocytosis as a prognostic factor for survival in patients with metastatic renal cell carcinoma.
TIL from renal-cell carcinoma: restimulation with tumor influences proliferation and cytolytic activity.
Treatment of patients with metastatic renal cell cancer: a RAND Appropriateness Panel.
Tumor-induced suppression of T lymphocyte proliferation coincides with inhibition of Jak3 expression and IL-2 receptor signaling. Role of soluble products from human renal cell carcinomas
Tumour Necrosis Factor - Misnomer and Therapeutic Target
VEGF and PDGF Receptors: Biologic Relevance and Clinical Approaches to Inhibition
VEGF: Biologic Aspects and Clinical Approaches
von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma.
VP16-213, cisplatinum, and adriamycin salvage therapy of refractory and/or recurrent nonseminomatous germ cell neoplasms.
Contributed to or performed: 
CANCER -PHILADELPHIA-
CURRENT ONCOLOGY REPORTS
EUROPEAN JOURNAL OF CANCER -A-
ONCOLOGY -WILLISTON PARK THEN HUNTINGTON THE MELVILLE NEW YORK-
ONCOLOGY -WILLISTON PARK THEN HUNTINGTON-
SEMINARS IN ONCOLOGY
Notes: 
Sources: 
VIAF LC LNB NKC NUKAT SUDOC
NTA
TEL
ZETO